BMRN · Biomarin Pharmaceutical Inc · Investor Relations

$57.23 +0.53 (+0.93%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$11.09B

193.69M

Volume · Nov 13 1.47M Avg daily vol (3M) 2.19M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date	Event	Type
2026-11-16 09:20 UTC	UBS Global Biopharma Conference	Conference
2026-11-17 11:30 UTC	Jefferies Global Healthcare Conference	Conference

Recent news

Date	Headline
2026-11-04	BioMarin to Participate in Upcoming Investor Conferences
2026-11-02	BioMarin Reports Third Quarter 2026 Financial and Operating Results
2026-10-29	BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
2026-10-26	BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
2026-10-09	BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
2026-10-05	BioMarin Appoints Cara Bauer as Chief People Officer
2026-10-02	BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
2026-09-14	BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
2026-09-09	BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
2026-09-02	BioMarin to Participate in Upcoming Investor Conferences
2026-09-01	BioMarin Announces Close of the Alesta Therapeutics Acquisition
2026-08-31	BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
2026-08-18	BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
2026-08-10	BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
2026-08-06	BioMarin Reports Second Quarter 2026 Financial and Operating Results
2026-07-30	BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
2026-07-27	BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
2026-07-13	U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia
2026-06-16	BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
2026-05-20	BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
2026-05-18	BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-04	BioMarin Reports First Quarter 2026 Financial and Operating Results
2026-05-02	BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
2026-04-27	BioMarin Completes Acquisition of Amicus Therapeutics
2026-04-27	BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET

Past events

Date	Event	Type
2026-11-11	Stifel Healthcare Conference	Conference
2026-11-02	BioMarin Pharmaceutical Third Quarter 2026 Conference Call	Earnings call
2026-09-14	Morgan Stanley 24th Annual Global Healthcare Conference	Conference
2026-09-10	Citi's 2026 Biopharma Back to School Conference	Conference
2026-09-10	Cantor Global Healthcare Conference 2026	Conference
2026-09-09	Wells Fargo 21st Annual Healthcare Conference	Conference
2026-08-12	Canaccord Genuity 46th Annual Growth Conference	Conference
2026-08-06	BioMarin Pharmaceutical Second Quarter 2026 Conference Call	Earnings call
2026-05-04	BioMarin Pharmaceutical First Quarter 2026 Conference Call	Earnings call
2026-03-11	Barclays 28th Annual Global Healthcare Conference	Conference
2026-03-10	Jefferies 2026 Biotech on the Bay Summit	Conference
2026-03-09	Leerink 2026 Global Healthcare Conference	Conference
2026-03-04	TD Cowen 46th Annual Health Care Conference	Conference
2026-02-23	BioMarin Pharmaceutical Fourth Quarter and Full Year 2025 Conference Call	Earnings call
2026-01-12	44th Annual J.P. Morgan Healthcare Conference	Conference
2025-12-19	BioMarin Pharmaceutical Inc. Business Update	Event
2025-11-18	Jefferies Global Healthcare Conference	Conference
2025-10-27	BioMarin Pharmaceutical Third Quarter 2025 Conference Call	Earnings call
2025-09-09	Morgan Stanley Global Healthcare Conference	Conference
2025-09-04	Wells Fargo Healthcare Conference	Conference
2025-09-03	Cantor Global Healthcare Conference	Conference
2025-08-04	BioMarin Pharmaceutical Second Quarter 2025 Conference Call	Earnings call
2025-05-16	BioMarin Pharmaceutical Inc. Business Update	Event
2025-05-01	BioMarin Pharmaceutical First Quarter 2025 Conference Call	Earnings call
2025-03-04	TD Cowen 45th Annual Healthcare Conference	Conference

Source: https://investors.biomarin.com/overview/default.aspx

Key facts CIK 1048477 CUSIP 09061G101 13F (30d) 453 filings 397 filers Visit website Investor relations